| FENFLURAMINE |
Fintepla® |
UCB AUSTRALIA PROPRIETARY LIMITED |
Lennox-Gastaut Syndrome (LGS) |
Nov 2025 |
Recommended |
| ENCORAFENIB BINIMETINIB |
Braftovi® Mektovi® |
PIERRE FABRE AUSTRALIA PTY LTD |
Non-small cell lung cancer (NSCLC) |
Nov 2025 |
Recommended |
| DENOSUMAB |
Stoboclo® Osenvelt® |
CELLTRION HEALTHCARE AUSTRALIA PTY LTD |
Osteoporosis Giant cell tumour of bone Bone metastases |
Nov 2025 |
Recommended |
| ONASEMNOGENE ABEPARVOVEC |
Zolgensma® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Spinal muscular atrophy (SMA) |
Nov 2025 |
Recommended |
| PEMBROLIZUMAB |
Keytruda® |
MERCK SHARP & DOHME (AUSTRALIA) PTY LTD |
Head and neck squamous cell carcinoma (HNSCC) |
Nov 2025 |
Recommended |
| IPTACOPAN |
Fabhalta® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Complement 3 glomerulopathy (C3G) |
Nov 2025 |
Not Recommended |
| CETRORELIX |
Femvi® |
SUN PHARMA ANZ PTY LTD |
Assisted Reproductive Technology (ART) |
Nov 2025 |
Recommended |
| RETIFANLIMAB |
Zynyz® |
SPECIALISED THERAPEUTICS ALIM PTY LTD |
Squamous cell anal carcinoma (SCAC) |
Nov 2025 |
Deferred |
| BELANTAMAB MAFODOTIN |
Blenrep® |
GLAXOSMITHKLINE AUSTRALIA PTY LTD |
Relapsed and/or refractory multiple myeloma (MM) |
Nov 2025 |
Not Recommended |
| BIMEKIZUMAB |
Bimzelx® |
UCB AUSTRALIA PROPRIETARY LIMITED |
Severe chronic plaque psoriasis (CPP) |
Nov 2025 |
Recommended |
| TAFASITAMAB |
Minjuvi® |
SPECIALISED THERAPEUTICS ALIM PTY LTD |
Relapsed and/or refractory follicular lymphoma (FL) |
Nov 2025 |
Deferred |
| VEDOLIZUMAB |
Entyvio® |
TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD. |
Severe Crohn disease (CD) Moderate to severe ulcerative colitis (MSUC) |
Nov 2025 |
Not Recommended |
| GLYCOPYRRONIUM |
Axhidrox® |
ACTOR PHARMACEUTICALS PTY LTD |
Primary axillary hyperhidrosis |
Nov 2025 |
Recommended |
| EFGARTIGIMOD ALFA |
Vyvgart® |
ARGENX AUSTRALIA PTY. LTD. |
Generalised myasthenia gravis (gMG) |
Nov 2025 |
Recommended |
| OMAVELOXOLONE |
Skyclarys® |
BIOGEN AUSTRALIA PTY LTD |
Friedreich’s ataxia |
Nov 2025 |
Recommended |
| RETIFANLIMAB |
Zynyz® |
SPECIALISED THERAPEUTICS ALIM PTY LTD |
Merkel cell carcinoma (MCC) |
Nov 2025 |
Deferred |
| SPESOLIMAB |
Spevigo® |
BOEHRINGER INGELHEIM PTY LTD |
Prevention of generalised pustular psoriasis flares |
Nov 2025 |
Not Applicable |
| TUCATINIB |
Tukysa® |
PFIZER AUSTRALIA PTY LTD |
Breast cancer |
Nov 2025 |
Recommended |
| ZANUBRUTINIB |
Brukinsa® |
BEIGENE AUS PTY LTD |
Mantle cell lymphoma (MCL) Waldenstrom macroglobulinaemia (WM) Chronic lymphocytic
leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Nov 2025 |
Recommended |
| CALCIPOTRIOL WITH BETAMETHASONE |
Actobet® |
ACTOR PHARMACEUTICALS PTY LTD |
Chronic stable plaque type psoriasis vulgaris |
Nov 2025 |
Recommended |
| AFLIBERCEPT |
Eydenzelt® |
CELLTRION HEALTHCARE AUSTRALIA PTY LTD |
Subfoveal choroidal neovascularisation (CNV) due to pathologic myopia (PM) |
Nov 2025 |
Recommended |
| WHEY PROTEIN FORMULA SUPPLEMENTED WITH AMINO ACIDS, LONG CHAIN POLYUNSATURATED FATTY
ACIDS, VITAMINS AND MINERALS, AND LOW IN PROTEIN, PHOSPHATE, POTASSIUM AND LACTOSE |
Renastart® |
VITAFLO AUSTRALIA PTY LIMITED |
Chronic Renal Failure |
Nov 2025 |
Not Applicable |
| TOFERSEN |
Qalsody® |
BIOGEN AUSTRALIA PTY LTD |
Amyotrophic lateral sclerosis (ALS) |
Nov 2025 |
Not Recommended |
| SEMAGLUTIDE |
Wegovy® |
NOVO NORDISK PHARMACEUTICALS PTY. LIMITED |
Established cardiovascular disease (eCVD) with obesity |
Nov 2025 |
Recommended |
| TESTOSTERONE |
AndroFeme 1® |
LAWLEY PHARMACEUTICALS PTY LTD |
Hypoactive sexual desire dysfunction (HSDD) |
Nov 2025 |
Not Recommended |
| ESTRADIOL WITH PROGESTERONE |
Bijuva® |
THERAMEX AUSTRALIA PTY LTD |
Vasomotor symptoms in post menopausal women |
Nov 2025 |
Recommended |
| DURVALUMAB |
Imfinzi® |
ASTRAZENECA PTY LTD |
Muscle invasive bladder cancer (MIBC) |
Nov 2025 |
Recommended |
| FEZOLINETANT |
Veoza® |
ASTELLAS PHARMA AUSTRALIA PTY LTD |
Moderate to severe menopause-related vasomotor symptoms (VMS) |
Nov 2025 |
Recommended |
| POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL |
Systane® |
ALCON LABORATORIES (AUSTRALIA) PTY LTD |
Severe dry eye syndrome |
Nov 2025 |
Recommended |
| LURBINECTEDIN |
Zepzelca® |
SPECIALISED THERAPEUTICS PHARMA PTY LTD |
Small cell lung cancer (SCLC) |
Nov 2025 |
Not Recommended |
| ACALABRUTINIB |
Calquence® |
ASTRAZENECA PTY LTD |
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Nov 2025 |
Recommended |
| TOCILIZUMAB |
Avtozma® |
CELLTRION HEALTHCARE AUSTRALIA PTY LTD |
Severe active juvenile idiopathic arthritis Severe active rheumatoid arthritis Systemic
juvenile idiopathic arthritis Active giant cell arteritis |
Nov 2025 |
Recommended |
| RISDIPLAM |
Evrysdi® |
ROCHE PRODUCTS PTY LTD |
Spinal muscular atrophy (SMA) |
Nov 2025 |
Recommended |
| DELGOCITINIB |
Anzupgo® |
LEO PHARMA PTY LTD |
Chronic hand eczema (CHE) |
Nov 2025 |
Recommended |
| FEDRATINIB |
Inrebic® |
BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |
Myelofibrosis |
Nov 2025 |
Recommended |
| TEZEPELUMAB |
Tezspire® |
ASTRAZENECA PTY LTD |
Asthma |
Nov 2025 |
Recommended |
| PEGCETACOPLAN |
Syfovre® |
APELLIS AUSTRALIA PTY LTD |
Bilateral geographic atrophy (GA) secondary to age-related macular degeneration (AMD) |
Nov 2025 |
Recommended |
| FUTIBATINIB |
Lytgobi® |
TAIHO PHARMA OCEANIA PTY LTD |
Bile duct cancer (cholangiocarcinoma) |
Nov 2025 |
Deferred |
| TRASTUZUMAB DERUXTECAN |
Enhertu® |
ASTRAZENECA PTY LTD |
Gastric or gastroesophageal junction (G/GOJ) cancer |
Nov 2025 |
Not Recommended |
| DESMOPRESSIN |
Desmomed |
MEDSURGE HEALTHCARE PTY LTD |
Cranial diabetes insipidus Primary nocturnal enuresis |
Nov 2025 |
Recommended |
| GIVOSIRAN |
Givlaari® |
MEDISON PHARMA AUSTRALIA PTY LIMITED |
Acute hepatic porphyria (AHP) |
Nov 2025 |
Recommended |
| MIRVETUXIMAB SORAVTANSINE |
Elahere® |
ABBVIE PTY LTD |
Epithelial ovarian, fallopian tube or primary peritoneal cancer |
Nov 2025 |
Recommended |
| NITISINONE |
Orfadin® |
A. MENARINI PTY LTD |
Hereditary tyrosinaemia Type 1 (HT-1) |
Nov 2025 |
Recommended |